Abstract :
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious condition associated with antiresorptive and antiangiogenic drugs, commonly used in treating osteoporosis and various cancers. The pathogenesis is multifactorial, involving impaired bone remodelling, infection, reduced angiogenesis, and immune suppression. MRONJ is more prevalent among cancer patients than those treated for osteoporosis. Clinically, it presents with exposed necrotic bone, pain, swelling, and secondary infections, significantly affecting the quality of human life. Diagnosis is clinical, supported by imaging and patient history. Management includes conservative or surgical approaches, with prevention being the most effective strategy. A multidisciplinary approach involving dentists, oncologists, and oral surgeons is essential for early diagnosis and treatment planning to minimize complications and improve patient outcomes. The purpose of this review is to shed light on the road map for clinical and radiographic diagnosis, prevention, and management of medication-related osteonecrosis of the jaw (MRONJ).
Keyword :
MRONJ, Osteonecrosis, Bisphosphonates, Denosumab, Jaw necrosis, Antiresorptive therapy.